PURPOSE: Advances in chemotherapy and supportive care have slowly improved survival rates for patients with high-risk neuroblastoma. The focus of many of these chemotherapeutic advances has been dose intensification. In this phase II trial involving children with advanced neuroblastoma, we used a program of induction chemotherapy followed by tandem high-dose, myeloablative treatments (high-dose therapy) with stem-cell rescue (HDT/SCR) in rapid sequence. PATIENTS AND METHODS: Patients underwent induction chemotherapy during which peripheral-blood stem and progenitor cells were collected and local control measures undertaken. Patients then received tandem courses of HDT/SCR, 4 to 6 weeks apart. Thirty-nine patients (age 1 to 12 years) were assessable, and 70 cycles of HDT/SCR were completed. RESULTS: Pheresis was possible in the case of all patients, despite their young ages, with an average of 7.2 x 10(6) CD34(+) cells/kg available to support each cycle. Engraftment was rapid; median time to neutrophil engraftment was 11 days. Four patients who completed the first HDT course did not complete the second, and there were three deaths due to toxicity. With a median follow-up of 22 months (from diagnosis), 26 of 39 patients remained event-free. The 3-year event-free survival rate for these patients was 58%. CONCLUSION: A tandem HDT/SCR regimen for high-risk neuroblastoma is a feasible treatment strategy for children and may improve disease-free survival.
PURPOSE: Advances in chemotherapy and supportive care have slowly improved survival rates for patients with high-risk neuroblastoma. The focus of many of these chemotherapeutic advances has been dose intensification. In this phase II trial involving children with advanced neuroblastoma, we used a program of induction chemotherapy followed by tandem high-dose, myeloablative treatments (high-dose therapy) with stem-cell rescue (HDT/SCR) in rapid sequence. PATIENTS AND METHODS: Patients underwent induction chemotherapy during which peripheral-blood stem and progenitor cells were collected and local control measures undertaken. Patients then received tandem courses of HDT/SCR, 4 to 6 weeks apart. Thirty-nine patients (age 1 to 12 years) were assessable, and 70 cycles of HDT/SCR were completed. RESULTS: Pheresis was possible in the case of all patients, despite their young ages, with an average of 7.2 x 10(6) CD34(+) cells/kg available to support each cycle. Engraftment was rapid; median time to neutrophil engraftment was 11 days. Four patients who completed the first HDT course did not complete the second, and there were three deaths due to toxicity. With a median follow-up of 22 months (from diagnosis), 26 of 39 patients remained event-free. The 3-year event-free survival rate for these patients was 58%. CONCLUSION: A tandem HDT/SCR regimen for high-risk neuroblastoma is a feasible treatment strategy for children and may improve disease-free survival.
Authors: Elizabeth A Sokol; Roger Engelmann; Wenjun Kang; Navin Pinto; Adam Starkey; Hollie Lai; Helen Nadel; Barry L Shulkin; Yonglin Pu; Daniel Appelbaum; Gregory A Yanik; Susan L Cohn; Samuel G Armato; Samuel Volchenboum Journal: Pediatr Blood Cancer Date: 2018-09-10 Impact factor: 3.167
Authors: Meaghan Granger; Stephan A Grupp; Morris Kletzel; Cynthia Kretschmar; Arlene Naranjo; Wendy B London; Lisa Diller Journal: Pediatr Blood Cancer Date: 2012-06-28 Impact factor: 3.167
Authors: A V Desai; M B Heneghan; Y Li; N J Bunin; S A Grupp; R Bagatell; A E Seif Journal: Bone Marrow Transplant Date: 2016-05-09 Impact factor: 5.483
Authors: Stephan A Grupp; Eline Luning Prak; Jean Boyer; Kenyetta R McDonald; Suzanne Shusterman; Edward Thompson; Colleen Callahan; Abbas F Jawad; Bruce L Levine; Carl H June; Kathleen E Sullivan Journal: Clin Cancer Res Date: 2012-10-23 Impact factor: 12.531
Authors: Stephan A Grupp; Michael Verneris; Paul M Sondel; Laurence J N Cooper Journal: Biol Blood Marrow Transplant Date: 2008-01 Impact factor: 5.742
Authors: Wendy L Hobbie; Thomas Moshang; Claire A Carlson; Elizabeth Goldmuntz; Nancy Sacks; Samuel B Goldfarb; Stephan A Grupp; Jill P Ginsberg Journal: Pediatr Blood Cancer Date: 2008-11 Impact factor: 3.167
Authors: Atmaram S Pai Panandiker; Lisa McGregor; Matthew J Krasin; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2009-08-11 Impact factor: 7.038